Shijiazhuang Pharmaceutical Group Enters Oncology Drug Market With Acquisition
This article was originally published in PharmAsia News
Executive Summary
Shijiazhuang Pharmaceutical Group and Dalian Yuanda Pharmaceutical have signed a wide-ranging agreement under which Shijiazhuang Pharmaceutical Group will invest RMB 200 million, and both companies will jointly develop the local market for Yuanda's leading anti-tumor drug Elemene. The two firms will conduct clinical trials of Elemene emulsion injection in China and the U.S., and will also launch new drugs. Elemene injection is the only State FDA-approved drug for treating intracranial tumors, while Elemene emulsion injection is slated for U.S. clinical trials next year. Yuanda will become a subsidiary of SPG and undergo a name change to align with the group. SPG has identified anti-tumor drugs as one of its key development areas and the collaboration marks its entry into the anti-tumor patented drug market. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.